The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

European pharmaceutical bosses have called on the EU to increase drug prices towards the much higher levels paid by the US, ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a new study.

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK825.00.

The following organizations have been chosen as Canada’s Greenest Employers for 2025 (employee count refers to full-time ...

The first-quarter 2025 earnings season for the Medical sector is about to pick up pace this week. The sector mainly comprises ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...